Work

SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.3093

Authors: Juneko E. Grilley-Olson, Brendan D. Curti, David C. Smith, Sanjay Goel, Thomas Gajewski, Svetomir Markovic, Olivier Rixe, David Lawrence Bajor, Martin Gutierrez, Timothy Kuzel, Amitkumar N. Mehta, Benny Amore, Abraham Guerrero, Zejing Wang, Andrew L. Coveler

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, University of Michigan, Albert Einstein College of Medicine, Montefiore Medical Center, University of Chicago Medical Center, Mayo Clinic, UNM Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Hackensack University Medical Center, Rush University Medical Center, University of Alabama at Birmingham, Seagen (United States), Seattle Cancer Care Alliance, University of Washington

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890430484

Cites:

Cited by: 28

Related to: 10